FDA-Approved Antibacterials and Echinocandins
Since 1955, a total of 12 peptide-based drugs with antimicrobial or antifungal properties have received approval from the Food and Drug Administration (FDA). Peptides present a promising opportunity to address serious infections that may be challenging to manage through other means. Peptides exhibit the capability to leverage various mechanisms, and in
openaire +4 more sources
The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis. [PDF]
Zubovskaia A, Vazquez JA.
europepmc +1 more source
Killing rates for caspofungin against Candida albicans after brief and continuous caspofungin exposure in the presence and absence of serum [PDF]
Berényi, Réka +6 more
core +1 more source
Antifungal Therapy in Candida Infective Endocarditis: A Comparison of Echinocandins and Other Treatment Regimens in a Nationwide Cohort Study. [PDF]
Kurland S +4 more
europepmc +1 more source
Deciphering the multidrug resistance paradigm in <i>Candida auris</i>. [PDF]
Santana DJ +3 more
europepmc +1 more source
Cost-Effectiveness of Once Weekly Rezafungin for the Treatment of Invasive Candidiasis in the United Kingdom. [PDF]
Muszbek N +10 more
europepmc +1 more source
Echinocandins and coagulation dysfunction events. [PDF]
Pham HT, Truong-Nguyen KH, Tran MH.
europepmc +1 more source
The fungal stronghold: biofilms in hemodialysis catheters, diagnostic pitfalls, and the challenge of catheter salvage. [PDF]
Shi J +5 more
europepmc +1 more source
The Silent Pandemic: Antifungal Resistance and the Future of Invasive Fungal Disease Management. [PDF]
Bagga R, Kavanoor Sridhar K.
europepmc +1 more source
Antifungal susceptibility profiles of candidemia isolates on the east coast of Peninsular Malaysia and reliability of Etest compared to Sensititre YeastOne. [PDF]
Abdullah SNS, Tzar MN, Othman SN.
europepmc +1 more source

